A Two Part, Phase I/II, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of the Safety and Efficacy of Topically Applied AMTX-100 CF in Adult Patients With Mild to Moderate Atopic Dermatitis
Latest Information Update: 09 May 2025
At a glance
- Drugs AMTX 100 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amytrx Therapeutics
Most Recent Events
- 17 Jan 2024 Status changed from recruiting to completed.
- 25 Jul 2023 Results presented in an Amytrx Therapeutics media release.
- 25 Jul 2023 According to a Amytrx Therapeutics media release, data from the phase1 part of the study were presented at the Revolutionizing Atopic Dermatitis (RAD) Conference.